Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine

This article was originally published in The Pink Sheet Daily

Executive Summary

Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.

You may also be interested in...

BIO Panel: Polymerase, Protease Inhibitor Combinations On The Horizon For Hepatitis C

Proof of concept study evaluating polymerase/protease inhibitor combinations for HCV could start within the next year, Vertex predicts.

Novartis/Idenix To Co-Promote Hep C Treatment, But Side Effects Delay Phase III Trial

Novartis has exercised its option to license valopicitabine from Idenix in spite of gastrointestinal side effects seen in clinical trials.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts